PE20150356A1 - Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue - Google Patents

Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue

Info

Publication number
PE20150356A1
PE20150356A1 PE2015000070A PE2015000070A PE20150356A1 PE 20150356 A1 PE20150356 A1 PE 20150356A1 PE 2015000070 A PE2015000070 A PE 2015000070A PE 2015000070 A PE2015000070 A PE 2015000070A PE 20150356 A1 PE20150356 A1 PE 20150356A1
Authority
PE
Peru
Prior art keywords
dengue
dengue virus
vaccine compositions
against infection
virus
Prior art date
Application number
PE2015000070A
Other languages
English (en)
Spanish (es)
Inventor
Jiansheng Yao
Yves Girerd-Chambaz
Isabelle Legastelois
Nathalie Mantel
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Sanofi Pasteur
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur filed Critical Sanofi Pasteur
Publication of PE20150356A1 publication Critical patent/PE20150356A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/295—Polyvalent viral antigens; Mixtures of viral and bacterial antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24111—Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PE2015000070A 2012-07-24 2013-07-24 Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue PE20150356A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP12305908 2012-07-24
EP12305911 2012-07-25

Publications (1)

Publication Number Publication Date
PE20150356A1 true PE20150356A1 (es) 2015-03-20

Family

ID=48856641

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2015000070A PE20150356A1 (es) 2012-07-24 2013-07-24 Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue

Country Status (15)

Country Link
US (1) US20150265695A1 (enExample)
EP (1) EP2877207A1 (enExample)
JP (1) JP2015524422A (enExample)
KR (1) KR20150036593A (enExample)
CN (1) CN104812408A (enExample)
AU (1) AU2013295016A1 (enExample)
BR (1) BR112015001313A2 (enExample)
CA (1) CA2878599A1 (enExample)
GT (1) GT201500005A (enExample)
HK (1) HK1212905A1 (enExample)
MX (1) MX2015000446A (enExample)
PE (1) PE20150356A1 (enExample)
PH (1) PH12014502875A1 (enExample)
SG (1) SG11201500439RA (enExample)
WO (1) WO2014016362A1 (enExample)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3166063A1 (en) 2013-03-15 2014-09-25 Takeda Vaccines, Inc. Compositions and methods for dengue virus chimeric constructs in vaccines
MY187896A (en) * 2013-06-21 2021-10-27 Merck Sharp & Dohme Dengue virus vaccine compositions and methods of use thereof
TWI852899B (zh) * 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
CA2960102C (en) * 2014-09-11 2023-10-24 Vlp Therapeutics, Llc Flavivirus virus like particle
MX383329B (es) * 2014-12-22 2025-03-13 Merck Sharp & Dohme Llc Composiciones de vacuna para el virus del dengue y metodos de uso de las mismas.
EP3316905A1 (en) 2015-07-03 2018-05-09 Sanofi Pasteur Concomitant dengue and yellow fever vaccination
WO2017023839A1 (en) 2015-08-03 2017-02-09 The United States Of America As Represented By The Secretary Of The Navy Immune enhancing recombinant dengue protein
RS65084B1 (sr) * 2015-09-29 2024-02-29 Boehringer Ingelheim Animal Health Usa Inc Vakcine čestica sličnih virusu (vlp) parvovirusa pasa (cpv) i njihova upotreba
US11531029B2 (en) 2017-05-08 2022-12-20 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Methods and compositions for the detection of flavivirus infections
SG11202002933TA (en) 2017-10-05 2020-04-29 Sanofi Pasteur Compositions for booster vaccination against dengu
EP3730620A4 (en) 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZING ANTIGEN VACCINE AND METHOD OF ITS MANUFACTURING
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A
IL298307A (en) 2018-09-05 2023-01-01 Takeda Vaccines Inc Dengue fever vaccine unit dose and its administration
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
CA3139328A1 (en) * 2019-05-15 2020-11-19 Codagenix Inc. Attenuated yellow fever virus and uses thereof for the treatment of cancer
CN120271718A (zh) * 2024-01-05 2025-07-08 北京昌平实验室 针对寨卡/登革病毒的重组抗原、其疫苗组合物及其应用

Family Cites Families (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
FR2649013B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Vaccins et vecteurs de principes actifs fluides contenant une huile metabolisable
FR2649012B1 (fr) 1989-07-03 1991-10-25 Seppic Sa Emulsions multiphasiques injectables
GB9326253D0 (en) 1993-12-23 1994-02-23 Smithkline Beecham Biolog Vaccines
US6254873B1 (en) 1995-04-17 2001-07-03 The United States Of America As Represented By The Secretary Of The Army Inactivated dengue virus vaccine
AU6093296A (en) 1995-06-07 1996-12-30 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Infectious dengue 2 virus pdk-53 as quadravalent vaccine
ES2345614T3 (es) 1997-02-28 2010-09-28 Sanofi Pasteur Biologics Co. Vacunas quimericas de flavivirus.
GB9711990D0 (en) 1997-06-11 1997-08-06 Smithkline Beecham Biolog Vaccine
GB9718901D0 (en) 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
CA2302554C (en) 1997-09-05 2007-04-10 Smithkline Beecham Biologicals S.A. Oil in water emulsions containing saponins
US7227011B2 (en) * 1998-06-04 2007-06-05 United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Nucleic acid vaccines for prevention of flavivirus infection
JP2002540171A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱４型ウイルスワクチン
CA2365411A1 (en) 1999-03-26 2000-10-05 Walter Reed Army Institute Of Research Attenuated dengue-2 virus vaccine
EP1165130A2 (en) 1999-03-26 2002-01-02 Walter Reed Army Institute of Research Attenuated dengue-3 virus vaccine
JP2002540169A (ja) 1999-03-26 2002-11-26 ウォルター リード アーミー インスティテュート オブ リサーチ 弱毒化デング熱１型ウイルスワクチン
IL147857A0 (en) * 1999-08-02 2002-08-14 American Cyanamid Co RESCUE OF MUMPS VIRUS FROM cDNA
US7094411B2 (en) 2000-02-16 2006-08-22 The United States Of America As Represented By The Department Of Health And Human Services Avirulent, immunogenic flavivirus chimeras
ATE412738T1 (de) 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
AT410634B (de) 2001-02-21 2003-06-25 Franz X Dr Heinz Attenuierte lebendimpfstoffe
JP2005518332A (ja) 2001-05-23 2005-06-23 デンドレオン コーポレイション 細胞表面のプロテアーゼにより活性化される結合体およびその治療的使用
JP2005501532A (ja) 2001-06-01 2005-01-20 アカンビス インコーポレーティッド キメラフラビウイルスベクター
AU2002330672A1 (en) 2001-07-25 2003-02-17 Genset S.A. Gmg-1 polynucleotides and polypeptides and uses thereof
HUE037330T2 (hu) * 2002-05-03 2018-08-28 The Government Of The Us Secretary Department Of Health And Human Services rDEN3/4delta30(ME), rDEN2/4delta30(ME) vagy rDEN1/4delta30(ME) rekombináns kiméra dengue virus, amely 30 nukleotidos deléciót tartalmaz (delta 30) a 4-es típusú dengue genom 3' nem-transzlálódó régiójában, ahol a szóban forgó 30 nukleotidos deléció megfelel a TL2 nyél-hurok szerkezetnek
WO2003101397A2 (en) 2002-05-31 2003-12-11 Acambis, Inc. Tetravalent dengue vaccines
CN1852734B (zh) * 2003-09-17 2010-12-01 杜克大学 共有/祖先免疫原
JP5197362B2 (ja) * 2005-06-17 2013-05-15 サノフィ・パスツール デング熱セロタイプ１弱毒株
BRPI0613287A2 (pt) * 2005-06-17 2010-12-28 Sanofi Pasteur cepa do vìrus da dengue-2 vivo atenuada, composição imunogênica, composição de vacina, ácido nucléico isolado, poliproteìna isolada codificadas pela seq id n .1 ou fragmentos desta e fragmento da poliproteìna
AR054822A1 (es) 2005-07-07 2007-07-18 Sanofi Pasteur Emulsion inmuno adyuvante
WO2007021672A2 (en) 2005-08-10 2007-02-22 Acambis Inc. Vaccination against dengue virus infection
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
US7968102B2 (en) * 2006-01-13 2011-06-28 Sanofi Pasteur S.A. Dengue chimeric viruses
FR2896162B1 (fr) 2006-01-13 2008-02-15 Sanofi Pasteur Sa Emulsion huile dans eau thermoreversible
FR2903605A1 (fr) 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2906724B1 (fr) 2006-10-04 2009-03-20 Sanofi Pasteur Sa Methode d'immunisation contre les 4 serotypes de la dengue.
FR2909286B1 (fr) 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
WO2008115314A2 (en) * 2007-01-31 2008-09-25 Sanofi Pasteur Biologics Co. Flavivirus vaccine vector against influenza virus
WO2009134717A1 (en) * 2008-04-30 2009-11-05 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services, Centers For Disease Control And Prevention Chimeric west nile/dengue viruses
EP2143440A1 (fr) 2008-07-09 2010-01-13 Sanofi Pasteur Agent stabilisant et composition vaccinale comprenant un ou plusieurs flavivirus vivants atténués
CN106421743A (zh) * 2009-07-29 2017-02-22 贝恩德·赫尔穆特·阿达姆·雷姆 聚合物微粒及其用途
US8900596B2 (en) * 2009-11-18 2014-12-02 The Board Of Regents Of The University Of Texas System Physicochemical (PCP) based consensus sequences and uses thereof
GB201007531D0 (en) 2010-05-05 2010-06-23 Imp Innovations Ltd Composition
WO2011146933A2 (en) * 2010-05-21 2011-11-24 University Of Pittsburgh-Of The Commonwealth System Of Higher Education Universal dengue virus sequences and methods of use
WO2012051491A1 (en) * 2010-10-14 2012-04-19 The United States Of America, As Represented By The Secretary National Institutes Of Health Compositions and methods for controlling neurotropic viral pathogenesis by micro-rna targeting
EP3932422A1 (en) * 2012-07-24 2022-01-05 Sanofi Pasteur Vaccine compositions for the prevention of dengue virus infection

Also Published As

Publication number Publication date
CA2878599A1 (en) 2014-01-30
PH12014502875A1 (en) 2015-02-23
GT201500005A (es) 2015-10-13
MX2015000446A (es) 2015-03-12
SG11201500439RA (en) 2015-02-27
CN104812408A (zh) 2015-07-29
AU2013295016A1 (en) 2015-01-29
WO2014016362A1 (en) 2014-01-30
JP2015524422A (ja) 2015-08-24
EP2877207A1 (en) 2015-06-03
HK1212905A1 (zh) 2016-06-24
US20150265695A1 (en) 2015-09-24
BR112015001313A2 (pt) 2017-08-01
KR20150036593A (ko) 2015-04-07

Similar Documents

Publication Publication Date Title
PE20150356A1 (es) Composiciones de vacuna para la prevencion contra la infeccion por el virus del dengue
CL2018003769A1 (es) Una cepa del virus atenuado de la peste porcina africana desarrollada racionalmente que, protege contra la infección por el virus parental georgia 2007 aislado.
MX2018007860A (es) Vacunas recombinantes contra el zika.
CY1119284T1 (el) ΣΩΜΑΤΙΔΙΑ ΠΑΡΟΜΟΙΑ ΜΕ ΙΟ ΓΛΥΚΟ-ΠΡΩΤΕΪΝΗΣ ΛΥΣΣΑΣ (VLPs)
AR080313A1 (es) Composiciones de virus de moquillo canino (cdv) recombinante y sus usos
AR090470A1 (es) Vacuna contra el virus sincicial respiratorio (rsv)
MX373884B (es) Variante de la proteína pcv2 orf2 y partículas similares al virus compuestas por ésta.
AR069882A1 (es) Circovirus porcino, molecula de acido nucleico aislada que lo codifica, composicion inmunogenica que lo comprende, vector que comprende por lo menos una molecula de acido nucleico exogena que codifica una proteina de circovirus porcino y metodos para inmunizar un cerdo contra la infeccion virica o e
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
BR112012033767A2 (pt) processo para produzir um vírus de interesse, para remover um agente adventício, e para remover um agente adventício, vírus,e, composição imunogênica ou vacina.
EA201391515A1 (ru) Инактивированная вакцина вируса денге
EA201991041A1 (ru) Вакцина против свиного парвовируса и вируса свиного репродуктивного и респираторного синдрома и способы ее получения
MX2013010620A (es) Adenovirus de aves del serotipo 4 (fadv-4) no patogénico y vector viral del mismo.
UY33297A (es) Composiciones farmaceuticas que comprenden un polipéptido que comprende al menos un motivo cxxc y antígenos heterólogos y usos de las mismas
MX383330B (es) Particula tipo virus de flavivirus.
UY32457A (es) Vacuna del virus del dengue inactivado
EA201390812A1 (ru) Лиофилизированные вирусные составы
EA201500643A1 (ru) Парвовирус свиней 5а, способы применения и вакцина
MX2018010958A (es) Vacuna para virus de zika atenuado vivo.
MX2018015506A (es) Vacuna contra virus de bronquitis infecciosa.
JO3281B1 (ar) مركبات بينزوفوران لمعالجة عدوى فيروس إلتهاب الكبد الوبائي
MX385295B (es) Expresión recombinante de la proteína orf2 de pcv2b en células de insecto.
EA201500140A1 (ru) Ослабленные вакцины от свиного гриппа и способы их получения и применения
PH12015501721A1 (en) Porcine parvovirus 5b, methods of use and vaccine
NI201700080A (es) Composiciones de vacuna para el virus del dengue y métodos de uso de las mismas.

Legal Events

Date Code Title Description
FD Application declared void or lapsed